SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

10 Nov 2022 Evaluate
Net sales declined -24.14%  to  Rs. 1121.72 million from Rs. 1478.58 millions.The Company to register a -71.04%  fall in the net profit for the quarter ended September 2022.A decline of 541.47 millions was observed in the OP in the quarter ended September 2022 from 971.04 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1121.72 1478.58 -24.14 2135.27 2248.00 -5.01 5300.49 3912.45 35.48
Other Income 26.05 33.21 -21.56 49.62 52.60 -5.67 75.77 49.77 52.24
PBIDT 541.47 971.04 -44.24 877.50 1144.96 -23.36 2215.62 1781.51 24.37
Interest 237.55 168.87 40.67 243.36 178.61 36.25 41.98 40.80 2.89
PBDT 303.92 802.17 -62.11 634.14 966.35 -34.38 2173.64 1740.71 24.87
Depreciation 29.73 24.63 20.71 58.58 49.40 18.58 101.18 67.61 49.65
PBT 274.19 777.54 -64.74 575.56 916.95 -37.23 2072.46 1673.10 23.87
TAX 105.57 195.33 -45.95 154.44 257.35 -39.99 554.35 437.16 26.81
Deferred Tax 0.91 -1.90 -147.89 3.91 44.07 -91.13 32.46 6.94 367.72
PAT 168.62 582.21 -71.04 421.12 659.60 -36.16 1518.11 1235.94 22.83
Equity 160.97 146.37 9.97 160.97 146.37 9.97 160.97 146.37 9.97
PBIDTM(%) 48.27 65.67 -26.50 41.10 50.93 -19.31 41.80 45.53 -8.20

Supriya Lifescience Share Price

638.20 -24.15 (-3.65%)
24-Apr-2026 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.80
Dr. Reddys Lab 1323.00
Cipla 1287.45
Zydus Lifesciences 929.65
Lupin 2267.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×